Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4184.00 +1.9% SILVER 57.41 +2.7% COPPER 6.56 −1.4% OIL 97.75 +2.8% PALLADIUM 1137.25 +3.7% STND 0.060 −7.7% B 0.560 −1.8% HBM 34.31 −0.6% NTR 98.56 −0.9% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.190 −11.6% CLCH 1.10 +0.0% NSU 0.170 +9.7% WM 0.085 +0.0% YGT 0.180 +5.9% EVI 0.500 +0.0% ADZ 0.125 +0.0% MINK 0.075 +0.0% DNO 0.300 +0.0% RRRL 0.150 +0.0% GOLD 4184.00 +1.9% SILVER 57.41 +2.7% COPPER 6.56 −1.4% OIL 97.75 +2.8% PALLADIUM 1137.25 +3.7% STND 0.060 −7.7% B 0.560 −1.8% HBM 34.31 −0.6% NTR 98.56 −0.9% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.190 −11.6% CLCH 1.10 +0.0% NSU 0.170 +9.7% WM 0.085 +0.0% YGT 0.180 +5.9% EVI 0.500 +0.0% ADZ 0.125 +0.0% MINK 0.075 +0.0% DNO 0.300 +0.0% RRRL 0.150 +0.0%
Other Routine +

Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration

Bausch + Lomb Executes H1 Roadmap with AREDS3 Launch Amidst Debt Refinancing and Earnings Growth

By The Northwire Desk — AI Analysis Apr 23, 2026 · 07:00 BLCO · 21.89 BAUSCH + LOMB CORPORATION
Executive Summary
  • Bausch + Lomb announced the publication of a narrative review in Ophthalmology and Therapy regarding B vitamins' role in reducing Age-Related Macular Degeneration (AMD) risk.
  • The company is launching PreserVision AREDS3 eye vitamins, combining B-vitamin complexes with AREDS2 nutrients.
  • Clinical findings from the WAFACS Study suggest a 34% reduction in AMD risk and 41% reduction in visually significant AMD with specific B6, B9, and B12 concentrations.
  • Product availability is confirmed for the U.S., with expected major retailer distribution by June 2026.
  • A long-term clinical trial is being planned to further evaluate efficacy of the new formulation.
Material Impact
  • The news confirms execution of a strategic roadmap item announced at the November 2025 Investor Day (Consumer Segment Launches: PreserVision® AREDS3 formulation – launch H1 2026).
  • As the launch was previously disclosed in guidance and investor presentations, this announcement is largely priced in and expected by the market.
  • The scientific review supports the product's value proposition but does not introduce new revenue streams beyond the existing vitamin portfolio expansion.
  • No material surprise regarding financial targets or regulatory hurdles; it aligns with the company's stated H1 2026 timeline.
BLCO · Price
Company Overview
  • Bausch + Lomb operates across three segments: Vision Care (contact lenses, vitamins), Surgical (equipment, IOLs), and Pharmaceuticals (dry eye treatments).
  • Flagship projects include the enVista intraocular lens platform, MIEBO dry-eye treatment, and the Elios laser system for glaucoma.
  • The company is transitioning from a Bausch Health subsidiary to an independent entity, focusing on margin expansion and pipeline monetization.
  • Strategic focus remains on premium IOLs (enVista Envy) and consumer health vitamins (PreserVision).
Read the original news release →

More from BAUSCH + LOMB CORPORATION

Jul 01, 2026 · 07:00

Dry Eye Survey Reinforces Premium Pricing Power, But Lacks Catalyst to Break Recent Consolidation

Other Jun 01, 2026 · 06:59

Bausch + Lomb Expands Dry Eye Portfolio with Preservative-Free Blink Launch; Execution on $7B Pipeline Continues Amid Margin Expansion

Financings May 19, 2026 · 07:00

Bausch + Lomb Executes H1 2026 Launch Plan Amidst Margin Expansion Push

Other May 07, 2026 · 07:00

Bausch + Lomb Expands Surgical Portfolio with European Bi-Blade+ Launch Amidst Guidance Raise

Other May 06, 2026 · 07:15

Bausch + Lomb Pipeline Webinar Confirms Long-Term Growth Narrative, But Near-Term Surgical Headwinds Persist Despite Q1 Guidance Raise

Other Apr 30, 2026 · 07:00

Bausch + Lomb Pipeline Validation Follows Q1 Guidance Raise Amidst Margin Expansion

Other